Fapon Showcases Local Manufacturing Solutions at MEDICA 2026 in Düsseldorf
Fapon's Local Manufacturing Solutions at MEDICA 2026
Fapon, a global leader in life sciences, is gearing up to showcase its local manufacturing solutions and a comprehensive portfolio of in vitro diagnostic (IVD) products at MEDICA 2026, taking place from November 16 to 19 in Düsseldorf, Germany. With a focus on supporting manufacturers of in vitro diagnostic devices, Fapon is committed to advancing local production capabilities and providing reliable sourcing of diagnostic materials.
At the MEDICA trade show, Fapon will highlight its local manufacturing solutions, which encompass a wide array of diagnostic methods including chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), clinical biochemistry, point-of-care testing (POCT), and molecular diagnostics (MDx). Leveraging its deep technological expertise and industry experience, Fapon aims to assist global diagnostic manufacturers with comprehensive technology transfer, integrated diagnostic solutions, and dependable raw material sourcing. This initiative is designed to empower partners in their efforts to bolster local production and respond to evolving regional market demands.
Fapon's offerings include flexible collaboration models that integrate technology transfer and localization support, covering everything from basic raw materials and bulk reagents to custom development, production, and registration support. By blending technical expertise, reagent formulation, and production know-how, the company aids partners in establishing or expanding local IVD manufacturing capabilities—from test development all the way through to local production and commercialization.
Apart from localization services, Fapon will present its all-in-one IVD solutions, merging IVD raw materials, reagent services, and open system instruments. Fapon's proficiency spans antibody discovery, process development, reagent formulation, and customization, guiding diagnostic manufacturers through various stages of product development and production. One notable example of Fapon's innovative development capabilities is its blood-based Alzheimer’s disease (AD) testing solution, which supplies raw materials and bulk reagents for critical biomarkers such as p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. These integrated capabilities offer flexible technical and product support to partners looking to develop and expand their diagnostic portfolios.
Another highlight of Fapon’s exhibition will be its recombinant quality control (QC) materials and calibration raw materials, engineered to ensure consistent analytical performance and reliable supply. Through recombinant expression technology, these materials help mitigate supply variability and biosafety risks associated with natural sourced materials while maintaining high homogeneity from batch to batch. Assessment evaluations showed that the RF dilution linearity demonstrated an R² value of 0.9989, while clinical comparison tests indicated an R² value of 0.9924, illustrating strong linearity and correlation during evaluations.
Production lots can be tailored with work volumes of 0.8 L, 2 L, 6 L, or 60 L in vessels up to 200 L, with batch sizes determined by client demand, quarterly production cycles, and available stock ensuring reliable supply. Additionally, Fapon’s Authorized Economic Operator (AEO) status and overseas warehouses further enhance its global delivery capabilities. The portfolio encompasses key diagnostic markers such as RF, CRP, CK-MB, HIV/HIV-P24, HBV, and ToRCH, supporting applications in clinical biochemistry, CLIA, ELISA, and POCT.
With 25 years of experience in the IVD industry, over 1,400 patent applications, and partnerships in more than 70 countries and regions, Fapon continues to drive innovation in diagnostics and global collaboration. Through its integrated technological capabilities, comprehensive product portfolio, and localization-focused services, Fapon is dedicated to helping partners accelerate diagnostic development and strengthen local production of IV diagnostic devices.
Visitors are invited to connect with the Fapon team at Hall 3, Stand D95 during MEDICA 2026 to explore collaboration opportunities and learn more about Fapon's IVD solutions and services.
About Fapon
Fapon is a major global player in life sciences, revolutionizing research and development in diagnostics and therapies through an innovative model that combines AI with a closed-loop system of dry and wet lab experiments. This approach significantly accelerates the discovery and translation of new biomarkers and targets. The company has established an integrated business structure that unifies AI-driven innovative discovery, one-stop diagnostic solutions, and groundbreaking therapies, addressing the entire spectrum of health management throughout the product lifecycle, thereby promoting the swift development of precision medicine. For more information, follow us on LinkedIn (Fapon) or visit our website at https://en.faponbiotech.com/. To arrange a meeting, please contact [email protected]